Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 3 episodes of urinary incontinence over a 3-day period~* History of Multiple Sclerosis (MS)~* Urinary incontinence not adequately controlled by anticholinergic medication~Exclusion Criteria:~* Current use of intermittent catheter or indwelling catheter to manage urinary incontinence~* Previous or current botulinum toxin therapy of any serotype for any urological condition~* Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks~* Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
- Placebo (Normal Saline) (Type: OTHER): Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).